Company won't help study pitting cheap and expensive versions of its eye drug

WASHINGTON - What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients C$63 per treatment and the other C$2,100? In the case of Genentech Inc., nothing....More